Literature DB >> 21270844

Atherosclerosis in 2010: new therapeutic insights.

Steven E Nissen1.   

Abstract

Controversies in the treatment of atherosclerosis include uncertainty about the benefits of fibric acid derivatives, whether inhibition of cholesterol ester transfer protein is helpful or harmful, and about the benefits of statins in patients with renal failure. Key studies in 2010 contributed to the resolution of these long-standing controversies.

Entities:  

Mesh：

Year:  2011        PMID： 21270844     DOI： 10.1038/nrcardio.2010.208

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  10 in total

1.  Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.

Authors: 
Journal:  Am Heart J       Date:  2010-09-18       Impact factor: 4.749

2.  Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity.

Authors:  K Hirano; S Yamashita; N Nakajima; T Arai; T Maruyama; Y Yoshida; M Ishigami; N Sakai; K Kameda-Takemura; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-06       Impact factor: 8.311

3.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

4.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

5.  Effects of combination lipid therapy in type 2 diabetes mellitus.

Authors:  Henry N Ginsberg; Marshall B Elam; Laura C Lovato; John R Crouse; Lawrence A Leiter; Peter Linz; William T Friedewald; John B Buse; Hertzel C Gerstein; Jeffrey Probstfield; Richard H Grimm; Faramarz Ismail-Beigi; J Thomas Bigger; David C Goff; William C Cushman; Denise G Simons-Morton; Robert P Byington
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

6.  Safety of anacetrapib in patients with or at high risk for coronary heart disease.

Authors:  Christopher P Cannon; Sukrut Shah; Hayes M Dansky; Michael Davidson; Eliot A Brinton; Antonio M Gotto; Michael Stepanavage; Sherry Xueyu Liu; Patrice Gibbons; Tanya B Ashraf; Jennifer Zafarino; Yale Mitchel; Philip Barter
Journal:  N Engl J Med       Date:  2010-11-17       Impact factor: 91.245

7.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Authors:  A Keech; R J Simes; P Barter; J Best; R Scott; M R Taskinen; P Forder; A Pillai; T Davis; P Glasziou; P Drury; Y A Kesäniemi; D Sullivan; D Hunt; P Colman; M d'Emden; M Whiting; C Ehnholm; M Laakso
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

8.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

9.  Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

Authors:  Margaret E Brousseau; Ernst J Schaefer; Megan L Wolfe; LeAnne T Bloedon; Andres G Digenio; Ronald W Clark; James P Mancuso; Daniel J Rader
Journal:  N Engl J Med       Date:  2004-04-08       Impact factor: 91.245

Review 10.  Study of Heart and Renal Protection (SHARP).

Authors:  Colin Baigent; Martin Landry
Journal:  Kidney Int Suppl       Date:  2003-05       Impact factor: 10.545
  10 in total
  1 in total

Review 1.  Fibrates for secondary prevention of cardiovascular disease and stroke.

Authors:  Deren Wang; Bian Liu; Wendan Tao; Zilong Hao; Ming Liu
Journal:  Cochrane Database Syst Rev       Date:  2015-10-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.